GW Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in response to its patent application for a metered dose spray device for sublingual delivery of Sativex liquid cannabis extract formulation. The application serial number is 13/606,742.
GW CEO Justin Gover commented, “This Notice of Allowance directed to the Sativex delivery device comes soon after the 13/607,897 Notice of Allowance directed to a method of sublingual delivery of the Sativex pharmaceutical formulation. Not only does GW have claims directed to the method of sublingual delivery of the Sativex formulation, but it also has claims directed to the device within which it is contained. In total, we now have seven different patent families containing one or more pending or issued patents relating to Sativex.”
Sativex is approved in the the UK, Spain, Germany, Denmark, the Czech Republic, Sweden, New Zealand, and Canada, and Almirall, which holds the marketing rights in most of Europe, filed additional applications for Sativex for the treatment of spasticity in multiple sclerosis in 2012.
The product is not currently approved in the US, but GW says that it intends to submit an NDA for Sativex for the treatment of pain due to cancer. The product is currently in Phase 3 clinical development for that indication.
Read the GW Pharmaceuticals press release.
